Pulmonary Arterial Hypertension Market Report 2026

The pulmonary arterial hypertension market size has grown strongly in recent years. It will grow from $9.15 billion in 2025 to $9.94 billion in 2026 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to rising prevalence of pulmonary arterial hypertension, limited early diagnosis capabilities, high unmet medical needs, availability of conventional drugs, growing awareness among healthcare professionals.

The pulmonary arterial hypertension market size is expected to see strong growth in the next few years. It will grow to $13.75 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to development of novel therapies, expansion of telemedicine, increasing government healthcare initiatives, rising adoption of combination therapies, growth in specialized treatment centers. Major trends in the forecast period include personalized pulmonary hypertension therapies, advanced drug delivery systems, combination therapy development, telehealth and remote patient monitoring, emerging regional treatment centers.

The growing number of clinical trials for drug development is expected to support the growth of the pulmonary arterial hypertension market in the coming years. Clinical trials are research studies carried out to assess the safety, efficacy, and potential side effects of new drugs or therapeutic approaches in humans. An increase in clinical trials targeting pulmonary arterial hypertension can result in the development of more effective treatment options, improvements in patient quality of life, enhanced safety and efficacy outcomes, earlier access to innovative therapies, and the identification of more cost-effective treatments. For example, in May 2023, according to Xtalks, a Canada-based provider of life science webinars and virtual events, a total of 452,604 clinical studies were registered on ClinicalTrials.gov as of May 17, 2023, with 64,838 studies actively recruiting participants. Therefore, the rising number of clinical trials for drug development is contributing to the expansion of the pulmonary arterial hypertension market.

Major companies operating in the pulmonary arterial hypertension market are introducing advanced therapies, such as OPSYNVI, to offer improved treatment options that enhance patient outcomes and quality of life for individuals affected by this serious condition. For instance, in March 2024, Johnson & Johnson, a US-based multinational company specializing in pharmaceuticals, biotechnology, and medical technologies, launched OPSYNVI for the long-term treatment of adults with pulmonary arterial hypertension. OPSYNVI is indicated for patients who are either newly diagnosed or already receiving therapy with an endothelin receptor antagonist (ERA), a phosphodiesterase-5 (PDE5) inhibitor, or both. It is also appropriate for patients maintained on stable doses of macitentan 10 mg and tadalafil 40 mg administered as separate tablets.

In May 2024, Gossamer Bio, a US-based biopharmaceutical company focused on treatments for pulmonary arterial hypertension (PAH), entered into a partnership with Chiesi Farmaceutici S.p.A. Through this collaboration, both companies aim to combine their expertise to enhance the treatment of pulmonary arterial hypertension and accelerate the development of therapies for pulmonary hypertension associated with interstitial lung disease (PH-ILD). Chiesi Farmaceutici S.p.A. is an Italy-based pharmaceutical company.

Major companies operating in the pulmonary arterial hypertension market are United Therapeutics Corporation, Acceleron Pharma Inc., Actelion Pharmaceuticals US Inc., Bayer AG, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Liquidia Technologies Inc., Lupin Pharmaceuticals Inc., Natco Pharma Ltd., Pfizer Inc., Sandoz AG, Teva Pharmaceutical Industries Ltd., Zydus Pharmaceutical USA Inc., Merck KGaA, Novartis International AG, Bristol-Myers Squibb Company, AstraZeneca plc, Daiichi Sankyo Company Limited.

North America was the largest region in the pulmonary arterial hypertension market in 2025. The regions covered in the pulmonary arterial hypertension market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pulmonary arterial hypertension market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the pulmonary arterial hypertension market by increasing import costs for active pharmaceutical ingredients and advanced drug delivery systems. The oral and prostacyclin drug segments, particularly in regions like Asia-Pacific and Latin America, are most impacted due to dependency on imported raw materials. While tariffs raise production costs and may limit access in certain markets, they also encourage local manufacturing investments and innovation in cost-efficient drug formulations, potentially improving regional self-sufficiency and long-term market resilience.

The pulmonary arterial hypertension market research report is one of a series of new reports that provides pulmonary arterial hypertension market statistics, including pulmonary arterial hypertension industry global market size, regional shares, competitors with a pulmonary arterial hypertension market share, detailed pulmonary arterial hypertension market segments, market trends and opportunities, and any further data you may need to thrive in the pulmonary arterial hypertension industry. This pulmonary arterial hypertension market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pulmonary arterial hypertension is a condition characterized by abnormally high blood pressure that damages the arteries in the lungs and the right side of the heart. In this chronic and progressive disorder, the walls of the pulmonary arteries become narrowed and stiff. Drugs used to treat pulmonary arterial hypertension work by relaxing the muscles in blood vessel walls, improving blood flow through the lungs, or counteracting substances that cause blood vessels to constrict.

The primary classes of pulmonary arterial hypertension drugs include endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE-5) inhibitors, prostacyclin and prostacyclin analogs, and soluble guanylate cyclase (sGC) stimulators. Endothelin receptor antagonists are a type of targeted therapy used to treat patients with pulmonary hypertension, helping to slow disease progression and potentially reverse certain aspects of heart and lung damage. These drugs are administered via oral, intravenous or subcutaneous, and inhalational routes, and are distributed through retail and online channels.

The pulmonary arterial hypertension market includes revenues earned by entities by idiopathic, heritable, and drug and toxin-induced. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.